Latest News

8th December, 2021

Thelper receives 50% funding coverage for Industrial PhD project

Thelper is pleased to announce that we have received 50% funding coverage from the Norwegian Research Council in December 2021 for the Industrial PhD project: “Development and preclinical documentation of First-in-Class Immunotherapy against triple negative breast cancer”, which will run from 2022 to 2026.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK